Dopamine agonist monotherapy in Parkinson's disease and potential risk factors for dyskinesia: A meta-analysis of levodopa-controlled trials

European Journal of Neurology

Volumn 21, Issue 3, 2014, Pages 433-440

  Chondrogiorgi, M ^a   Tatsioni, A ^a   Reichmann, H ^b   Konitsiotis, S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Dopamine agonists; Dyskinesia; Levodopa; Meta analysis; Parkinson's disease

Indexed keywords

DOPAMINE AGONISTS; DYSKINESIA; LEVODOPA; META-ANALYSIS; PARKINSON'S DISEASE;

DATABASES, BIBLIOGRAPHIC; DOPAMINE AGONISTS; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE;

EID: 84893873270     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12318     Document Type: Article

References (40)

1. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Mov Disord 2007; 22: 1379-1389.
2. Baker WL, Silver D, White CM, et al. Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis. Parkinsonism Relat Disord 2009; 15: 287-294.
3. Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev 2008; 16: CD006564.
4. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010; 25: 2649-2653.
5. Higgins JPT, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med 2004; 23: 1663-1682.
6. Hely MA, Morris JG, Rail D, et al. The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years. J Neurol Neurosurg Psychiatry 1989; 52: 324-328.
7. Montastruc JL, Rascol O, Rascol A. A randomised controlled study of bromocryptine versus levodopa in previously untreated Parkinsonian patients: a 3-year follow-up. J Neurol Neurosurg Psychiatry 1989; 52: 773-775.
8. Rinne UK. Lisuride, a dopamine agonist in the treatment of early Parkinson's disease. Neurology 1989; 39: 336-339.
9. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocryptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993; 307: 469-472.
10. Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocryptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994; 57: 1034-1038.
11. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484-1491.
12. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000; 284: 1931-1938.
13. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET Study. Ann Neurol 2003; 54: 93-101.
14. Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004; 18: 733-746.
15. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET Study. Mov Disord 2006; 21: 343-353.
16. Chase TN. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998; 55(Suppl. 1): 1-9.
17. Juncos JL, Mouradian MM, Fabbrini G, Serrati C, Chase TN. Levodopa methyl ester treatment of Parkinson's disease. Neurology 1987; 37: 1242-1245.
18. Fernandez HH, Vanagunas A, Odin P, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism Relat Disord 2013; 19: 339-345.
19. Dupont E, Andersen A, Boas J, et al. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 1996; 93: 14-20.
20. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Neurology 1999; 53: 1012-1019.
21. Maratos EC, Jackson MJ, Pearce RK, Canizzaro C, Jenner P. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than L-DOPA in the MPTP-lesioned common marmoset (Callithrix jacchus). Exp Neurol 2003; 179: 90-102.
22. Blanchet PJ, Konitsiotis S, Chase TN. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine monkeys. J Pharmacol Exp Ther 1997; 283: 794-799.
23. Clarke CE, Boyce S, Robertson RG, Sambrook MA, Crossman AR. Drug-induced dyskinesia in primates rendered hemiparkinsonian by intracarotid administration of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). J Neurol Sci 1989; 90: 307-314.
24. Rose S, Scheller DK, Breidenbach A, et al. Plasma levels of rotigotine and the reversal of motor deficits in MPTP-treated primates. Behav Pharmacol 2007; 18: 155-160.
25. Warren Olanow C, Kieburtz K, Rascol O, et al. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord 2013; 28: 1064-1071.
26. Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol 2008; 15: 493-496.
27. Rascol O, Brooks D, Korczyn A, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-DOPA. Mov Disord 2006; 21: 1844-1850.
28. Cenci MA, Ohlin KE, Rylander D. Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia. Parkinsonism Relat Disord 2009; 15(Suppl. 3): S59-S63.
29. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71: 474-480.
30. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa responsive problems dominate at 15 years. Mov Disord 2005; 20: 190-199.
31. Benbir G, Ozekmekci S, Apaydin H, Delil S, Erginöz E. A hospital-based study: risk factors in development of motor complications in 555 Parkinson's disease patients on levodopa therapy. Clin Neurol Neurosurg 2006; 108: 726-732.
32. Fahn S. Is levodopa toxic? Neurology 1996; 47(6 Suppl. 3): S184-S195.
33. Paillé V, Brachet P, Damier P. Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease. NeuroReport 2004; 15: 561-564.
34. Guigoni C, Dovero S, Aubert I, et al. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. Eur J Neurosci 2005; 22: 283-287.
35. Pearce RK, Heikkilä M, Lindén IB, Jenner P. L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology 2001; 156: 402-409.
36. Nutt JG. Levodopa-induced dyskinesia: review, observations, and speculations. Neurology 1990; 40: 340-345.
37. Mones RJ, Elizan TS, Siegel GJ. Analysis of L-dopa induced dyskinesias in 51 patients with Parkinsonism. J Neurol Neurosurg Psychiatry 1971; 34: 668-673.
38. Möller JC, Eggert KM, Unger M, Odin P, Chaudhuri KR, Oertel WH. Clinical risk-benefit assessment of dopamine agonists. Eur J Neurol 2008; 15(Suppl. 2): 15-23.
39. Reiff J, Jost WH. Drug-induced impulse control disorders in Parkinson's disease. J Neurol 2011; 258(Suppl. 2): S323-S327.
40. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007; 6: 826-829.